From hours to minutes? Genentech says Ocrevus subcutaneous formulation works just as well as IV

To receive Roche’s multiple sclerosis drug Ocrevus, patients currently have to sit through two to four hours of infusion every six months. A year ago, Roche launched a Phase III study to test an idea: Can a new formulation cut down that time to 10 minutes?

New Phase III results…
Click here to view original post